import { Placeholder } from "@angular/compiler/src/i18n/i18n_ast";

const tsv_str = `
Session	Name	NameCh	Affiliations		ImgFileName		Description		Links
Keynote	Michael McKenna		Chief Surgical Officer, Akouos-Eli Lily		Michael_Mckenna.jpg		<p>Michael J. McKenna, M.D., is Chief Surgical Officer and Co-Founder of Akouos, (A Wholly Owned Subsidiary of Eli Lilly and Co).  He is a world-renowned neurologist with expertise in translational inner ear drug delivery research. For the past 15 years, Dr. McKenna led efforts to establish inner ear drug delivery systems to enable the development of hearing restoration therapies. Prior to founding Akouos, he held the Joseph B. Nadol, Jr. Chair and was the director of the Division of Otology and Neurotology at Massachusetts Eye and Ear and a professor of otolaryngology at Harvard Medical School.  Dr. McKenna’s laboratory shaped the field’s understanding of the molecular pathophysiology of otosclerosis through over three decades of pioneering research. He and his colleagues were the first to demonstrate an association between the COL1A1 gene and clinical otosclerosis. Dr. McKenna holds an M.D. from the University of Southern California School of Medicine, completed his otolaryngology residency at Harvard Medical School, and his fellowship in neurotology and skull base surgery at the House Ear Clinic.</p>
Keynote	Kornelia Polyak		Professor, Dana-Farber Cancer Institute		Kornelia_Polyak.jpg		<p>Kornelia Polyak, MD, PhD, is Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a co-leader of the Dana-Farber Harvard Cancer Center Cancer Cell Biology Program.  Dr. Polyak is an internationally recognized leader of breast cancer research. Her laboratory is dedicated to the study of human breast cancer with the goal of dissecting tumor evolution and use this information to improve the clinical management of breast cancer patients. Main areas of interests are: (1) breast cancer risk prediction and prevention, (2) drivers of tumor evolution, and (3) novel therapeutic targets. Dr. Polyak have received numerous awards including the Paul Marks Prize for Cancer Research, the AACR Outstanding Investigator Award for Breast Cancer Research, and the 14th Rosalind E. Franklin Award for Women in Science. She is a recipient of the NCI Outstanding Investigator award (2015 and 2022) and received a Distinguished Alumna Award from Weil-Cornell in 2020. Dr. Polyak is a fellow of the AAAS and the AACR Academy, member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. She is also an American Cancer Society Research Professor and received the 2023 AACR Distinguished Lectureship in Breast Cancer Research award.</p>		https://www.linkedin.com/in/kornelia-polyak-0064a31/
Opeining remarks	Jimmy Luo	羅維中	Scientist, Drug Product Development, Moderna		jimmy-luo.jpg		<p>Pei-Jung is an Analytical Development Scientist at Intellia Therapeutics, where she supports multiple pipelines for in vivo and ex vivo CRISPR-based gene therapy platforms targeting drug release. She holds a Ph.D. in Chemical Engineering from the University of Kentucky, with research focusing on biomaterial and cellular coatings for drug delivery. With a focus on designing robust analytical methods, she ensures precise product quality assessment and stringent regulatory compliance. During her postdoctoral research at the FDA, Pei-Jung conducted pivotal evaluations of molecule transport in cells subjected to bioprinting stress. At Eurofins PSS, she distinguished herself by pioneering the development and qualification of impurity and potency assays critical for autologous CAR-T therapy. Prior to Intellia, her contributions at Rubius Therapeutics focused on innovate novel analytical strategies for the characterization of allogenic Red-Cell Therapeutics™ (RCTs) and lentiviral vector (LVV) platforms. At Intellia, Pei-Jung continues to exemplify leadership, providing strategic guidance and mentorship to junior scientists, fostering a collaborative and innovative research environment. </p>		https://www.linkedin.com/in/jimmywcl
Opeining remarks	Ginnie Hu	胡金儒	Ph.D. Candidate, Harvard University		Ginnie_Hu.jpg		<p>N/A</p>		https://www.linkedin.com/in/chin-ju-ginnie-hu/
Panel#1 Infectiuos Disease	Dan H Barouch		Director of the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center		Dan_Barouch.jpg		<p>Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, and a member of the Ragon Institute of MGH, MIT, and Harvard. His laboratory focuses on studying the immunology and pathogenesis of viral infections and developing novel vaccine and treatment strategies. His group has led the development of vaccine candidates for HIV-1, Zika, SARS-CoV-2, tuberculosis, and influenza. His work contributed to the development of the Johnson & Johnson COVID-19 vaccine and the evaluation of multiple COVID-19 vaccines and therapeutics. He was elected to the American Society for Clinical Investigation (2009), Association of American Physicians (2013), and National Academy of Medicine (2020), and he received the King Faisal Prize in Medicine (2023).</p>		https://www.linkedin.com/in/danbarouch/
Panel#1 Infectiuos Disease	Wilfredo F. Garcia-Beltran		Clinician-Scientist Fellow at Ragon Institute of MGH, MIT, and Harvard		Wilfredo Garcia-Beltran.jpg		<p>N/A</p>		https://www.linkedin.com/in/wilfredo-garcia-beltran-md-phd-7a2bb21b2/
Panel#1 Infectiuos Disease	Anne Wyllie		Global Medical Affairs Lead, Pfizer		Anne_Wyllie.jpg		<p>Anne Wyllie, Ph.D. is the Global Medical Affairs Lead for Pediatric Pneumococcal Vaccines at Pfizer. Prior to joining Pfizer, she was a Principal Investigator at the Yale School of Public Health, where her work focused on improving the surveillance of respiratory pathogens in the community. She is widely recognized for validating and optimizing the use of saliva as a reliable, low-cost sample type for respiratory pathogen detection. For Streptococcus pneumoniae, her methods enhanced the detection of pneumococcal carriage across the lifespan, revealing previously underappreciated reservoirs of the pneumococcus in older adults—findings that continue to inform vaccination policy and strategy. During the COVID-19 pandemic, she led the development of SalivaDirect, an open-source qPCR protocol that expanded global access to equitable, scalable SARS-CoV-2 testing. Her work bridges laboratory innovation, public health implementation, and policy translation. She remains committed to advancing pathogen surveillance, increasing access to low-cost diagnostic tools, and supporting evidence-based vaccine strategies to improve population health.</p>		https://www.linkedin.com/in/anne-wyllie/
Panel#1 Infectiuos Disease	Nicolas Alan Menzies		Associate Professor of Global Health, Harvard T.H. Chan School of Public Health 		Nicolas Menzies.png		<p>Nick Menzies is Associate Professor of Global Health in the Department of Global Health and Population, and part of the core faculty of the Harvard Center for Health Decision Science. Dr. Menzies uses decision science and quantitative research to understand the consequences of policies to combat major infectious diseases and help design effective disease control programs when resources are limited. His research primarily addresses the intersection of HIV and tuberculosis (TB) epidemics in sub-Saharan Africa and other high-burden regions. His laboratory collaborates with various organizations, including the Centers for Disease Control and Prevention (CDC), the Gates Foundation, the World Health Organization (WHO), and the Global Fund Against AIDS, TB, and Malaria. Dr. Menzies holds a Bachelor of Dental Surgery from University of Otago, New Zealand, and an MPH and PhD from Harvard University. Prior to joining Harvard he worked with the Global AIDS Program at the U.S. Centers for Disease Control and Prevention, conducting economic evaluation and implementation research on HIV/AIDS control interventions in countries supported by the President's Emergency Plan for AIDS Relief (PEPFAR). In his prior work he was a hospital dentist in New Zealand.</p>		https://www.linkedin.com/in/nick-menzies-5ab9a35/
Panel#2 Personalized Medicine	Pei-Ken Hsu		Director, RNA Sciences, Sail Biomedicines		Pei-Ken Hsu.jpeg		<p>Pei-Ken has navigated through a diverse biomedical landscape from schizophrenia to sleep disorders and from organoid to CAR-T. He is the director of RNA Sciences at Sail BioMedicines, where he leads the advancement of the eRNA (circRNA) platform through iterative high-throughput design-build-test-learn cycles. In addition to spearheading platform innovation, he and his team play a pivotal role in cross-functional initiatives focused on innovative eRNA manufacturing approaches and the development of Sail’s therapeutic programs.</p><p>Pei-Ken has strong expertise in CRISPR, genome engineering and synthetic biology, with a particular focus on precise knock-in of large genetic circuits. He has successfully implemented and refined genome engineering technologies across multiple systems, including mouse embryos, human iPSCs, primary T cells, and in vivo models.</p><p>He earned his Bachelor of Science and Master of Science from National Taiwan University, followed by a Ph.D. in Neuroscience from Columbia University. After completing a postdoctoral fellowship at UCSF, he joined the transgenic core at Northwestern University as a manager. Prior to his role at Sail BioMedicines, Pei-Ken held scientific positions at Synthego, System1 Biosciences (Herophilus), ArsenalBio, and Nutcracker Therapeutics.</p>		https://www.linkedin.com/in/peikenhsu/
Panel#2 Personalized Medicine	Liang-Bo Wang		Sr. Scientist, Oncology Bioinformatics, Moderna		Liang-Bo_Wang.jpg		<p>Liang-Bo Wang is a Senior Scientist in Oncology Bioinformatics at Moderna, where he leads the development and validation of omics data pipelines for the company's cancer vaccine portfolio, with a focus on individualized neoantigen therapies (INT). Dr. Wang bridges software engineering and multi-omics analysis to enable robust tumor characterization and precise neoantigen prediction, supporting regulatory compliance and improved patient outcomes. He holds a Ph.D. in Computational and Systems Biology from Washington University in St. Louis, where his research focused on comprehensive characterization of human tumors using advanced technologies, including proteomics, single-cell sequencing, spatial transcriptomics, and multiplexed imaging. He contributed to major cancer research consortia such as TCGA, CPTAC, and HTAN, providing key insights into tumor heterogeneity and the tumor microenvironment. He is an active contributor to open-source communities and speakers at R and Python meetups. At Moderna, he continues to advance computational innovation in translational medicine, driving the evolution of personalized cancer vaccines from concept to clinical application.</p>		https://www.linkedin.com/in/liangbowang/
Panel#3 Aging	Sheng-Hong Chen		Associate Research Fellow, Academia Sinica		Sheng-Hong Chen.jpeg		<p>Biological rhythms orchestrate functions in space and time for organisms to develop, to adapt, and to survive. My lab is interested in revealing hidden biological rhythms and in deciphering their underlying regulatory principles for biological control. We take a multifaceted quantitative approach integrating concepts and methods in biology, mathematics, engineering and informatics. Rhythmic systems that we investigate include oscillators, toggle switches and trigger waves, especially those that govern cellular survival, death, and differentiation.</p>		https://www.linkedin.com/in/shenghong/
Panel#3 Aging	Kejun (Albert) Ying 		Postdoctoral Fellow, Stanford University		Albert_Ying.jpeg		<p>Kejun Ying, postdoctoral researcher studying aging systems biology at Stanford University (Wyss-coray lab) and Institute of Protein Design (Baker lab), NIH/NIA K00 fellow. Dr. Ying completed his Ph.D. in Biology (2025) and M.S. in Computational Science & Engineering (2024) from Harvard University in Dr. Vadim Gladyshev's lab. His contributions include developing the first causal inference-based aging clock (Nature Aging cover, 2024), creating ClockBase -- a platform integrating over two million biological age data highlighted in Nature Biotechnology News -- and developing MethylGPT, recognized in Science by Eric Topol as among the most promising biomedical large models. Dr. Ying is a core member of the Biomarkers of Aging Consortium, co-leads its Biolearn and Challenge project. His research has been published in various high-impact journals, including Nature Aging, Nature Review Genetics, Nature Medicine, and Nature Metabolism.		https://www.linkedin.com/in/kejun-albert-ying?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app
Panel#3 Aging	Raghav Sehgal		Director of data science, Healthy Longevity Clinics		RV_Sehgal.jpeg		<p>I am a computational biologist with over a decade of experience integrating data science and artificial intelligence into the biomedical field. I completed my PhD at Yale University, where I developed SYMPHONYAge, a patented biomarker that measures aging across 11 different organs from a single blood draw. This technology is now available to patients and clinicians through TruDiagnostic, where I also serve as a Scientific Advisory Board member. In addition to my academic work, I am a Scientific Principal at Longevity Tech Fund, a venture capital firm focused on investing in AI, digital health, medical devices, and diagnostics. My role involves evaluating investment opportunities, advising startups, and helping shape the future of longevity-focused innovation. Over the years, I have worked as a scientist, engineer, product manager, and entrepreneur, with projects spanning cancer prediction, metabolic regulation, and multi-omics. My research has been published in prestigious journals like Nature, and I have received multiple honors, including the Gruber Science Fellowship, the Impetus Aging Grant, and a spot on the Forbes 30 Under 30 list in 2025. 		https://www.linkedin.com/in/raghav-sehgal-yale?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app
Panel#3 Aging	Stan Wang		CEO & Founder, Thymmune Therapeutics		Stan Wang.jpeg		<p>N/A</p> 		https://www.linkedin.com/in/stanwang?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=ios_app
Panel#4 Consulting	Ting-Hui Wu		Vice President of Clinical Development, Mythic Therapeutics		Ting-Hui Wu.jpg		<p>Ting-Hui Wu is currently the Vice President of Clinical Development at Mythic Therapeutics. He leads the global development of MYTX-011, a novel pH-engineered ADC, and contributes to shaping Mythic’s ADC pipeline. Prior to joining Mythic, he led the development of a first-in-class mRNA epigenomic anticancer therapy at Omega Therapeutics. Prior to joining Omega, he served as an Engagement Manager in the Life Science Practice at McKinsey & Company, supporting biotech and pharmaceutical companies on pipeline/asset strategy, business development, and due diligence. Ting holds an M.D. from the National Taiwan University and completed his internal medicine and medical oncology training at the National Taiwan University Hospital. He also received an M.S. in cancer epidemiology from the Johns Hopkins Bloomberg School of Public Health.</p>		https://linkedin.com/in/ting-hui-wu-md-msc-ab535733/
Panel#4 Consulting	Ariel Yeh		Director of Business Development at Prime Medicine		panel 4_Ariel.jpg		<p>Dr. Ariel Yeh is a Business Development Director at Prime Medicine and a former consultant at McKinsey & Company. She earned her B.S. in Chemical Engineering (’14) and Ph.D. in Biological Engineering (’20) from Harvard University. Ariel was named to the Forbes 30 Under 30 list in 2021. She was the first employee at Prime Medicine, which went public in 2022 with a billion valuation. She holds 5+ patents licensed to NASDAQ-listed biotech firms, and her research has been published in Nature, Nature Biotechnology, Science Translational Medicine, and other journals.</p>		https://www.linkedin.com/in/ariel-wei-hsi-yeh-90065a94/
Panel#4 Consulting	Li-Chun Wang		President at LCWang Regulatory Consulting		panel 4_Li-Chun.jpg		<p>Li-Chun has 40 years industry drug development experience in the biopharmaceutical/biotech companies. Li-Chun has been in regulatory space for 17 years through her tenure with Bristol-Myers Squibb and Millennium/Takeda in the small molecules and with Solid in the AAV gene therapy.  Prior to transitioning into regulatory sciences, Li-Chun has led Sterile and Semi-solid Technology groups in Tech Ops at BMS supporting process transfer from R&D to the commercial manufacturing facilities for phase 3 sterile products and North America manufacturing support for 8 years. During the 13 years in BMS, Li-Chun also supported generic development for Apothecon Division and global testing standards in Worldwide QCQA. Prior to that, Li-Chun was Department Head of Pharmaceutics at Carter-Wallace for 10 years leading Preformulation and Dissolution groups. Overall, as a Regulatory CMC lead, Li-Chun has successfully secured two NDA/MAA, and rest of world approvals, led FDA meetings (Type C, EOP2, Pre-NDA, etc), executed CMC submissions to support global clinical trials (IND, IMPD, CTA, amendment, etc.), global registrations, and marketed products (AR, renewals, variations, etc).  Li-Chun received her BS in pharmacy from National Taiwan University and Ph.D. in Pharmaceutical Sciences from University of Connecticut, CT. She was invited speaker to several conferences on new drug development and regulatory in Taiwan and has served in AAPS Membership Strategic Oversight Committee and Regulatory Science Section in 2013.</p>		https://www.linkedin.com/in/li-chun-wang-05881928/
Special talk	Danny Chou		Associate Professor of Pediatrics (Endocrinology and Diabetes), Stanford University		danny-chou.jpg		<p>Danny Chou is an Associate Professor of Pediatrics (Endocrinology and Diabetes) at Stanford University. He received his PhD from Harvard University, working in the lab of Prof. Stuart Schreiber. His Ph.D. research involved the identification of suppressors of cytokine-induced apoptosis in pancreatic beta cells. He then moved to MIT, where he was a JDRF Postdoctoral Fellow in Department of Chemical Engineering. He worked under the guidance of Profs. Robert Langer and Daniel Anderson, focusing on the development of glucose-responsive insulin derivatives. Danny started his independent career in Department of Biochemistry at University of Utah in August, 2014. At Utah, Danny's research focused on protein and peptide therapeutics for the treatment in Type 1 Diabetes and other human diseases. In 2020, Danny moved his research lab to Stanford University to continue their efforts in developing novel insulin therapeutics. His laboratory has received funding support from NIH, DoD, JDRF and American Diabetes Association. Danny has received recognitions including an American Peptide Society Early Career Lectureship, Boulder Peptide Society Young Investigator Award, JDRF Career Development Award, Vertex Scholar, JDRF Postdoctoral Fellow and ADA Junior Faculty Award. Outside of his day job, he is also a well-known Key Opinion Leader (KOL) on Facebook, Instagram, and Threads, with 66,000 followers, specializing in popular science and career development.</p>		https://www.linkedin.com/in/dhcchou/
Trending Topic	Wei-Hung Weng		Research Scientist, Google Research		weng.jpg		<p>Wei-Hung Weng is a Research Scientist at Google DeepMind, focused on applying AI to advance scientific discovery and healthcare. His research at Google includes developing the AI co-scientist, the conversational medical AI system, AMIE, the medically fine-tuned large language model, Med-Gemini, and specialized AI models for analyzing medical audio and PPG data. He holds a PhD in Computer Science from MIT, an MMSc in Biomedical Informatics from Harvard, and an MD from Chang Gung University, Taiwan. He previously practiced as a physician and pathologist in Taiwan.<p>		https://www.linkedin.com/in/ckbjimmy/
Trending Topic	Jeffrey Ruffolo		Head of Protein Design, Profluent		N/A.jpg		<p>N/A</p>		https://www.linkedin.com/in/jeffreyruffolo/
Trending Topic	Chong Duan		Director, AI Lead, Pfizer		Chong_Duan.jpg		<p>Chong Duan is a Director, Imaging AI Lead in the Translational Clinical Sciences group within Pfizer's Research & Development organization. Chong has a PhD degree in MRI Biophysics from Washington University in St. Louis and a master's degree in computer science from Georgia Institute of Technology. In his role at Pfizer, Chong leads research collaborations with academics, AI companies, and non-profit organizations for imaging AI initiatives in oncology, cardiology, and other therapeutic areas.</p>		https://www.linkedin.com/in/chongduan/
Trending Topic	Emily Fang		President & CEO, InFocus Therapeutics		N/A.jpg		<p>N/A</p>		https://www.linkedin.com/in/emilyfang2/?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAABCiGUsB6tQBTa9vrkB7cbNnKpLCEzFz7p0
Career diagnosis roundtable	Hong-Ren Wang		President & CEO, PharmaEngine
Career diagnosis roundtable	Lewis Lau		Associate Director CMC project management,Alkeus Pharmaceuticals
Career diagnosis roundtable	Zoey Chou		Senior Project Manager- AI and Data CoE, IDEXX
Career diagnosis roundtable	Carolyn Hsu	許翠玲	Director of CMC operations, Aktis oncology
Career diagnosis roundtable	Shang-Chuen Wu	吳尚錞	Instructor, Harvard Medical School
Career diagnosis roundtable	Daniel Chou	周宏杰	Associate Professor,Stanford University
Career diagnosis roundtable	Ying-Ja Chen	陳映嘉	Solutions Architect, Healthcare & Life Sciences, NVIDIA
Career diagnosis roundtable	Yan-Jhu Su	蘇彥竹	
Career diagnosis roundtable	Ting-Wei Liao	廖庭尉	
Career diagnosis roundtable	Pei-Jung Wu	吳佩容	
Career diagnosis roundtable	George Chan	詹喬治	Life & Career Coach / Facilitator		George_Chan.jpg		<p>George 是一位職涯教練，投注十年的時間在引導與教練上，擁有教練時數超過三千小時與七百場工作坊的經驗。曾從台灣跨洋轉職，拿到數個 Offer，包括新加坡 TikTok、英國 Mozilla、美國 BD 等多個職位。最後選擇到美國 Amazon 擔任軟體工程師，後續將這求職過程中的學習轉化為一套完整、可遵循的框架，自 2021 年以來協助超過 200 位 mentees （SWE/PM/Data Scientist/Date Engineer/Business Analyst） 在九個月內拿到理想國家的 Offer。</p>
Career diagnosis roundtable		陳政儀	
Career diagnosis roundtable	Liang-Yuan Chiu	邱亮源	
Career diagnosis roundtable	Yvonne Hsieh		
Career diagnosis roundtable	Jerry Lin		
Career diagnosis roundtable		余慈顏	
Career diagnosis roundtable		蔡孟勳	
Career diagnosis roundtable		羅世皓
Breakfast 	Liang-Hui Chu		Director, Clinical Pharmacology, Immunovant		N/A.jpg		<p>Dr. Liang-Hui Chu is currently the Director of Clinical pharmacology in Immunovant since 2024. He is currently the Member of ACCP (American college of clinical pharmacology) in the ACCP publication committee 2024-2026. Before working in Immunovant, he was the associate director of clinical pharmacology in Takeda Pharmaceuticals. He received his PhD degree in Biomedical Engineering at Johns Hopkins University in 2015.</p>		https://www.linkedin.com/in/liang-hui-chu/
Breakfast 	Nelson Liu		Senior Medical Director, AztraZeneca 
Breakfast 	Vincent Tseng		Senior Data Scientist, Verily
Breakfast 	Hao-Wei Su		Staff Research Scientist, Google
Breakfast 	Gerogia Lin		
Breakfast 	Shih-Ying Wu		
Breakfast 	Sarah Chen		
Breakfast 	Jessica Huang	黃顗蓉	Technical consultant, mba candidate, MIT		Yi-Jung Huang-Jessica.JPG
Breakfast 	Hsuan-Ping Chang	張瑄玶	Associate Director, Translational PKPD, AstraZeneca
Breakfast 	Jeffiner Lu		Principal Research Scientist, Vertex Pharmaceuticals
Breakfast 	Ho-Chou Tu	杜荷洲	Director, Alnylam Pharmaceuticals
Breakfast 	Ming-Ju Tsai	蔡明儒	Senior Scientist, Computational Biology, Takeda
Breakfast 	Kai-Chih Huang	黃楷智	Senior Computational Biologist, Pfizer
Breakfast 	Shang-Chuen Wu	吳尚錞	Instructor, Harvard Medical School
Breakfast	Meng-Ju Wu	吳孟儒	Assistant Professor at the University of Massachusetts Chan Medical School		Meng-Ju Wu.jpeg		<p>Dr. Meng-Ju Wu completed his B.S. and M.S. in Life Science and Oral Biology at National Yang-Ming University. He earned his Ph.D. at Purdue University, focusing on epigenetic mechanisms in stem cells. He is currently an instructor at Massachusetts General Hospital, Department of Medicine, Harvard Medical School, where he researches IDH1 mutant intrahepatic cholangiocarcinoma. His work has revealed key insights into immune evasion and the effects of IDH inhibition. In October 2024, he will start his independent lab as an Assistant Professor at the University of Massachusetts Chan Medical School.</p>		https://www.linkedin.com/in/meng-ju-wu/
`;

const tsv_array = tsv_str
	.split('\n')
	.map(el => el.split('\t'))
	.filter(el => el[1])
	.map(el => {
		return {
			'name': el[1].trim() || null,
			'nameCh': el[2] || null,
			'affiliations': el[3] ? el[3].split(';') : [],
			'imgFileName': el[5] || 'placeholder.jpg',
			'links': el[9] ? el[9].split(';') : [],
			'description': el[7] || ''
		};
	});

const tsv_dict = {};

tsv_array.forEach(el => {
	el.name.trim() in Object.keys(tsv_dict)
		? false
		:  tsv_dict[el.name.trim()] = el;
});

export const speakersObj = tsv_dict;
